Ovid Therapeutics Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in New York, NY. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $7 million and a loss of $17 million (its filed statements).
Pre-revenue companyPharmaceutical PreparationsNew York, NYfilings since 20158 of 9 filed, 1 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a pre-revenue company: no meaningful revenue on file yet (industry code 2834), so it is read as a pre-revenue company; the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 5.8 out of ten, 8 of 9 metrics filed and 1 estimated: past 4.1 out of ten, present 5.6 out of ten, future 6.9 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 3.5 out of ten. 1 warning event since 2017; the latest 2025-02-13. 35th percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 3.3 out of ten. -56.8% a year over 5 filed years; profitable in 1 of 5. 33rd percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 5.8 out of ten. CrossAssetData estimate 5.8/10, confidence 20 of 100 (family median). 50th percentile among 295 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Financial health (present): 7.8 out of ten. ROE -13%: lost 13¢ per shareholder dollar. Leverage 13%: owes 13¢ per asset dollar. 78th percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 5.4 out of ten. top 46% of 314 in its family; net margin -240.1%. 54th percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 2.9 out of ten. bottom 29% of 315 in its family for leadership; chief executive since 2026. 29th percentile among 315 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 4.0 out of ten. bottom 41% of 272 in its family for room to expand. 41st percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 8.1 out of ten. top 19% of 307 in its family for growth drivers. 81st percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 8.6 out of ten. top 14% of 234 in its family for expectations against reality. 86th percentile among 234 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-03-18 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-13 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-03-18 for the period ended 2026-03-17 (on EDGAR). Newest filing: Form 144, 2026-08-24. Filings on record since 2015. Read from EDGAR 2026-10-12.
Who runs it
Alexander, Margaret A. (President and CEO); Levin, Jeremy M (Executive Chairman); Carter, Charles Ross (Chief Financial Officer); Rona, Jeffrey A (CBFO); Greka, Anna (director); Fitzgerald, Kevin Joseph (director); Friedman, Bart (director); Papadopoulos, Stelios (director); Bernstein, Karen (director); Duncan, Barbara Gayle (director). 10 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.